Arbutus Biopharma Corporation
ABUS
$2.72
-$0.03-1.09%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 2.15M | 4.66M | 4.65M | 6.69M | 6.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.15M | 4.66M | 4.65M | 6.69M | 6.25M |
| Cost of Revenue | 17.56M | 20.17M | 17.69M | 18.28M | 22.95M |
| Gross Profit | -15.42M | -15.51M | -13.04M | -11.59M | -16.70M |
| SG&A Expenses | 5.10M | 5.84M | 5.98M | 5.55M | 4.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.67M | 26.01M | 23.67M | 23.83M | 27.20M |
| Operating Income | -20.52M | -21.35M | -19.02M | -17.14M | -20.95M |
| Income Before Tax | -19.31M | -20.10M | -17.09M | -16.34M | -21.93M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -19.31M | -20.10M | -17.09M | -16.34M | -21.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.31M | -20.10M | -17.09M | -16.34M | -21.93M |
| EBIT | -20.52M | -21.35M | -19.02M | -17.14M | -20.95M |
| EBITDA | -20.16M | -20.98M | -18.68M | -16.81M | -20.65M |
| EPS Basic | -0.11 | -0.12 | -0.10 | -0.10 | -0.14 |
| Normalized Basic EPS | -0.07 | -0.07 | -0.07 | -0.06 | -0.08 |
| EPS Diluted | -0.12 | -0.12 | -0.10 | -0.10 | -0.14 |
| Normalized Diluted EPS | -0.07 | -0.07 | -0.07 | -0.06 | -0.08 |
| Average Basic Shares Outstanding | 168.59M | 167.51M | 166.06M | 161.64M | 155.60M |
| Average Diluted Shares Outstanding | 168.59M | 167.51M | 166.06M | 161.64M | 155.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
